Tag: AKBA

Finance

Biotech New Lows: Akebia Therapeutics (NASDAQ:AKBA), Galmed Pharmaceuticals (NASDAQ:GLMD), Tetralogic Pharmaceuticals (NASDAQ:TLOG), Dipexium Pharmaceuticals (NASDAQ:DPRX)

Akebia Therapeutics Inc. (NASDAQ:AKBA) offered 5.9 million shares in its Thursday IPO at $17 a share, the high end of the stock’s expected price range. Among other therapeutics, the biopharma company is developing a once-daily oral therapy for patients with kidney disease. Akebia Therapeutics, Inc. (NASDAQ:AKBA) stock performance was -0.99% in last session and finished the day at $20.00. Traded volume was 219,904 million shares … Continue reading Biotech New Lows: Akebia Therapeutics (NASDAQ:AKBA), Galmed Pharmaceuticals (NASDAQ:GLMD), Tetralogic Pharmaceuticals (NASDAQ:TLOG), Dipexium Pharmaceuticals (NASDAQ:DPRX)

Kevin Long
Finance

Stocks in News: Kinross (NYSE:KGC), Blonder Tongue Laboratories (NYSEMKT: BDR), Akebia Therapeutics (NASDAQ:AKBA), Rofin-Sinar (NASDAQ:RSTI), CarMax (NYSE:KMX)

Gold miner Kinross Gold Corporation (NYSE:KGC) posted adjusted earnings of $32.9 million or 3 cents per share in the second quarter of 2014, down 72.5% from adjusted earnings of $119.5 million or 10 cents per share in the year-ago quarter. Earnings per share also missed the Zacks Consensus Estimate of 4 cents per share. Kinross Gold Corporation (NYSE:KGC) belongs to Basic Materials sector. Its weekly … Continue reading Stocks in News: Kinross (NYSE:KGC), Blonder Tongue Laboratories (NYSEMKT: BDR), Akebia Therapeutics (NASDAQ:AKBA), Rofin-Sinar (NASDAQ:RSTI), CarMax (NYSE:KMX)

Jason Knox